Compare NFGC & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NFGC | DSGN |
|---|---|---|
| Founded | 2016 | 2017 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 928.8M | 819.6M |
| IPO Year | 2021 | 2021 |
| Metric | NFGC | DSGN |
|---|---|---|
| Price | $2.20 | $15.85 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $15.25 |
| AVG Volume (30 Days) | ★ 1.7M | 522.6K |
| Earning Date | 05-11-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3,542.00 | N/A |
| Revenue Next Year | $118.57 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.19 | $3.11 |
| 52 Week High | $3.59 | $17.25 |
| Indicator | NFGC | DSGN |
|---|---|---|
| Relative Strength Index (RSI) | 54.99 | 67.91 |
| Support Level | $1.85 | $9.25 |
| Resistance Level | $2.34 | $17.25 |
| Average True Range (ATR) | 0.13 | 1.24 |
| MACD | 0.02 | 0.16 |
| Stochastic Oscillator | 78.31 | 75.94 |
New Found Gold Corp is a mineral exploration company engaged in the acquisition, exploration and evaluation of resource properties with a focus on gold properties located in the Provinces of Newfoundland and Labrador and Ontario, Canada. The Company's exploration is focused on discovering and delineating gold resources. The Company has one material property: the Queensway Project located in Newfoundland, Canada (the Queensway Project).
Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.